Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03556280 · ClinicalTrials.gov registry record · NA

Multi-Center Study of Sensory Stimulation to Improve Brain Function

A NA study of Alzheimer Disease and Mild Cognitive Impairment, sponsored by Cognito Therapeutics.

Active
Registry status
NA
Development phase
60
Enrollment target
5
Study locations

NCT03556280: Active NA study of Alzheimer Disease and Mild Cognitive Impairment, sponsored by Cognito Therapeutics.

NCT03556280 is a NA study of Alzheimer Disease and Mild Cognitive Impairment that is active but no longer recruiting, run by Cognito Therapeutics. The registered enrollment target is 60 participants, below the 2,751-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (98% lower). The trial reports 5 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03556280, a NA study of Alzheimer Disease and Mild Cognitive Impairment, is active but no longer recruiting, sponsored by Cognito Therapeutics.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
60 participants
Enrollment target
5
Study locations

Study Summary

The Overture Study is a randomized, controlled, single-blind multi-center clinical trial using the GammaSense Stimulation system to study safety, tolerability, and efficacy in people with mild to moderate cognitive impairment.

Primary Outcome

A widely accepted, validated measure of cognitive function in Alzheimer's Disease consisting of 14 questions that result in a score ranging from 0 to 90 with higher scores representing greater cognitive impairment

Conditions Studied

Alzheimer Disease Mild Cognitive Impairment Dementia Cognitive Impairment Cognitive Decline Dementia Alzheimers Dementia, Mild Dementia of Alzheimer Type Dementia Alzheimer Type Cognitive Impairment, Mild

Interventions

  • DEVICE GammaSense Stimulation System (Active Settings)
  • DEVICE GammaSense Stimulation System (Sham Settings)

Study Locations (5)

Florida

  • Brain Matters Research - Delray Beach
  • Brain Matters Research - Stuart

Massachusetts

  • ActivMed Practices & Research, Inc - Methuen
  • Boston Center for Memory - Newton

New Jersey

  • The Cognitive and Research Center of New Jersey - Springfield

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2018-04-24
Est. Completion 2021-09
Phase NA
Cognito Therapeutics

2 total trials

What the registry record for NCT03556280 still lists

NCT03556280 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 2,751-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (98% lower).

The record links to 10 conditions, with Alzheimer Disease appearing as the primary indexed condition, and to 2 interventions - of which GammaSense Stimulation System (Active Settings) is the first listed.

NCT03556280 lists 5 locations in 3 states (Florida, Massachusetts, New Jersey).

Frequently Asked Questions

What is clinical trial NCT03556280 about?

NCT03556280 is a clinical study titled "Multi-Center Study of Sensory Stimulation to Improve Brain Function". The Overture Study is a randomized, controlled, single-blind multi-center clinical trial using the GammaSense Stimulation system to study safety, tolerability, and efficacy in people with mild to moderate cognitive impairment.

What is the current status of trial NCT03556280?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 60 participants. The study started on 2018-04-24. Estimated completion is 2021-09.

What conditions does trial NCT03556280 study?

This clinical trial studies the following conditions: Alzheimer Disease, Mild Cognitive Impairment, Dementia, Cognitive Impairment, Cognitive Decline.

What interventions are being tested in trial NCT03556280?

The interventions under investigation include: GammaSense Stimulation System (Active Settings) (DEVICE), GammaSense Stimulation System (Sham Settings) (DEVICE).

Who is sponsoring clinical trial NCT03556280?

This trial is sponsored by Cognito Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03556280 being conducted?

This trial has 5 study locations across Florida, Massachusetts, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Alzheimer Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03556280's enrollment target sits among peer trials

60 187th of 306 higher than 108 of 306 other Alzheimer Disease trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Alzheimer Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00576069 · 60 participants

    Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma

  • NCT01297400 · 60 participants · Phase 2

    Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns

  • NCT01734122 · 60 participants

    Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor

  • NCT01804634 · 60 participants · Phase 2

    Reduced Intensity Haploidentical BMT for High Risk Solid Tumors

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT03556280, the US trial registry maintained by the National Library of Medicine. NCT03556280 (small enrollment · multi site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.